• $1.6M
    Market Cap
  • 196.14%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
08/31/2025
Income Statement
Total Operating Revenue
76,338
N/A
Cost of Revenue
51,859
N/A
Gross Profit
24,479
N/A
Sales and Marketing Expense
N/A
N/A
Research and Development Expense
N/A
N/A
Depreciation and Amortization Expense
N/A
N/A
Total Operating Expenses
141,110
N/A
Operating Profit
-116,631
N/A
Interest Income
N/A
N/A
Interest Expense
-594
N/A
Interest Income and Expense and Net
-594
N/A
Total Nonoperating Income and Expense
-594
N/A
Income before Taxes
-117,225
N/A
Income Taxes
0
N/A
Extraordinary Items
N/A
N/A
Net Income
-117,225
N/A
Net Income from Continuing Operations Applicable to Common
-117,225
N/A
Basic EPS and Net Income
0.00
N/A
Diluted EPS and Net Income
0.00
N/A
Basic Weighted Average Shares
222.6M
N/A
Diluted Weighted Average Shares
222.6M
N/A
Balance Sheet
Cash and Cash Equivalents
477
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
477
N/A
Total Current Assets
1,977
N/A
Accumulated Depreciation
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
Total Long-Term Assets
N/A
N/A
Total Assets
111,742
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
341,105
N/A
Total Current Liabilities
397,449
N/A
Total Long-Term Debt
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
Total Liabilities
397,449
N/A
Retained Earnings
-922,691
N/A
Total Stockholders Equity
-285,707
N/A
Total Shares Outstanding
223.5M
N/A
Cash Flow
Cash from Operating Activities
46,481
N/A
Capital Expenditures
52,600
N/A
Cash from Investing Activities
-92,140
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
46,136
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow